The FDA approval of Sotyktu for psoriasis has both ignited and dampened prospects for smaller biotech stocks.

Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.

Revance Therapeutics claimed FDA approval for Daxxify. Ramping sales will take years.

Botox's dominance of the facial injections market is facing new competition.

Competitive drug prices are great for consumers. Turns out, they're good for industry, too.

It has one product on the market and up to four more launching by the end of 2023. The growth trajectory depends on execution.

JPMorgan each month publishes a roster of stocks representing its analysts' top ideas.

The bank made a list of 'signature picks, an eclectic portfolio culled from our research department's highest-conviction ideas.'

JPMorgan's top-idea list has stocks in three different categories: near-term, growth and value.

Tesla is expected to start production of its highly anticipated futuristic truck in 2023.

A development team led by Seth Rogen is working on a production that centers on a less well-known character with a nonetheless devoted following.

The Fed's preferred inflation gauge topped Street forecasts Friday, snuffing out hopes of a near-term change in the central bank's rate hiking plans.